TELCON RF PHARMACEUTICAL. Inc. (200230.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	61.8B	43.2B	37.9B	36.3B	27.8B
Cost of Revenue	45.1B	35.8B	27.6B	26.8B	25.2B
Gross Profit	16.7B	7.3B	10.3B	9.5B	2.6B
Operating Expenses
R&D Expense	680.3M	699.1M	722.9M	733.2M	1.2B
SG&A Expense	13.3B	1.8B	2.4B	4.7B	5.3B
General & Admin Expense	285.9M	396.4M	394.2M	329.5M	294.4M
Selling & Marketing Expense	1.0B	1.4B	2.1B	938.0M	904.2M
Other Expenses	2.3B	4.1B	7.2B	6.6B	169.5M
Total Operating Expenses	16.2B	6.6B	10.4B	5.5B	6.7B
Cost and Expenses	61.4B	42.5B	37.9B	32.3B	31.9B
Operating Income (EBIT)	445.9M	718.6M	(70.5M)	4.0B	(4.1B)
Non-Operating
Interest Income	1.0B	682.0M	325.0M	188.9M	54.7M
Interest Expense	4.0B	4.8B	3.8B	603.6M	1.1B
Net Interest Income	(2.9B)	(4.1B)	(3.4B)	(414.7M)	(1.0B)
Other Non-Op Income/Expense	(27.5B)	(12.1B)	(26.4B)	13.0B	(38.1B)
Non-Operating Income (excl Interest)	(4.3B)	—	22.7B	(10.5B)	37.0B
EBT (Pre-Tax Income)	(27.0B)	(11.4B)	(26.5B)	12.0B	(42.1B)
Income Tax Expense	(52.4M)	—	—	(2.0B)	(32.8M)
Bottom Line
Net Income	(17.5B)	(11.5B)	(26.3B)	13.9B	(42.1B)
Earnings from Cont. Ops	(27.0B)	(11.4B)	(26.5B)	13.9B	(42.1B)
Earnings from Discont. Ops	(569.1M)	—	—	—	—
Bottom Line Net Income	(17.5B)	(11.5B)	(26.3B)	13.9B	(42.1B)
Per Share
Basic EPS	(₩3,565)	(₩1,708)	(₩22,246)	₩2,244	(₩3,967)
Diluted EPS	(₩3,565)	(₩1,708)	(₩22,246)	₩2,244	(₩3,967)
Revenue Per Share	₩10,965	₩6,299	₩32,005	₩5,858	₩2,623
Shares
Basic Shares Outstanding	5.6M	6.9M	1.2M	6.2M	10.6M
Diluted Shares Outstanding	5.6M	6.9M	1.2M	6.2M	10.6M
Profitability Metrics
EBITDA	12.1B	5.5B	(18.2B)	16.8B	(36.8B)
D&A	5.8B	4.8B	4.5B	4.2B	4.3B
EBIT	(3.3B)	718.6M	(22.7B)	12.6B	(41.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026